Holen Sie sich die Stockscreener-App
2.775
6.92%
0.175
Schlusskurs vom Vortag:
$2.60
Offen:
$2.69
24-Stunden-Volumen:
770.89K
Relative Volume:
0.54
Marktkapitalisierung:
$254.96M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.15M
KGV:
-3.0495
EPS:
-0.91
Netto-Cashflow:
$-31.63M
1W Leistung:
+21.93%
1M Leistung:
+23.01%
6M Leistung:
+238.86%
1J Leistung:
+230.17%
1-Tages-Spanne:
$2.62
$2.815
1-Wochen-Bereich:
$2.08
$2.815
52-Wochen-Spanne:
$0.49
$2.85
Context Therapeutics Inc Stock (CNTX) Company Profile
Firmenname
Context Therapeutics Inc
Sektor
Branche
Telefon
267-225-7416
Adresse
2001 MARKET STREET, PHILADELPHIA
Compare CNTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
2.775 | 238.89M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.31 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
765.92 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
724.67 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.39 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.71 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Eingeleitet | Guggenheim | Buy |
| 2025-04-21 | Eingeleitet | William Blair | Outperform |
| 2025-01-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-11-25 | Eingeleitet | D. Boral Capital | Buy |
| 2024-05-16 | Eingeleitet | Piper Sandler | Overweight |
Context Therapeutics Inc Aktie (CNTX) Neueste Nachrichten
CNTX SEC FilingsContext Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
CNTX: Advancing three T-cell engager programs in solid tumors with key data milestones ahead - TradingView
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
OVID PE Ratio & Valuation, Is OVID Overvalued - Intellectia AI
UBS Maintains Buy on Sionna Therapeutics, Inc. (SION) March 02, 2026 - Meyka
CNTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CNTX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Wall Street Zen Downgrades Context Therapeutics (NASDAQ:CNTX) to Sell - MarketBeat
Context Therapeutics Reaches Governance Settlement, Plans Annual Elections - The Globe and Mail
CNTX Should I Buy - Intellectia AI
Context Therapeutics (NASDAQ: CNTX) targets annual director elections in governance shift - Stock Titan
Equities Analysts Issue Forecasts for CNTX FY2025 Earnings - Defense World
Research Analysts Offer Predictions for CNTX FY2025 Earnings - MarketBeat
H.C. Wainwright Maintains Buy on FULC Fulcrum Therapeutics, Inc. Feb 24, 2026 - Meyka
Context Therapeutics (NASDAQ:CNTX) Stock Rating Upgraded by Lifesci Capital - Defense World
Lifesci Capital Upgrades Context Therapeutics (NASDAQ:CNTX) to "Strong-Buy" - MarketBeat
Context Therapeutics (CNTX) awards 270,000 stock options to Chief Legal Officer - Stock Titan
CFO at Context Therapeutics (CNTX) receives 275,000-share stock option grant - Stock Titan
Context Therapeutics (CNTX) CEO granted 815,000 stock options - Stock Titan
What is Context Therapeutics Inc. s 5 year growth outlookJuly 2025 Institutional & Target Return Focused Stock Picks - mfd.ru
Context Therapeutics Presents CTIM-76 Phase 1 Trial in Progress at ASCO 2025 - MSN
Is Context Therapeutics Inc. a potential multi bagger2025 Technical Patterns & Smart Money Movement Tracker - mfd.ru
Shorts Report: Is H2O America stock forming a triangle patternQuarterly Earnings Report & Consistent Income Trade Recommendations - baoquankhu1.vn
Geopolitics Watch: Whats the fair value of TMHC stockJuly 2025 Opening Moves & High Accuracy Buy Signal Tips - baoquankhu1.vn
Profit Recap: What is Context Therapeutics Incs book value per shareJuly 2025 Update & High Conviction Buy Zone Alerts - baoquankhu1.vn
Fund Flows: How does Context Therapeutics Inc perform in inflationary periodsEarnings Recap Summary & High Yield Stock Recommendations - baoquankhu1.vn
Great Point reveals 5.1% Context Therapeutics (CNTX) stake in 13G/A - Stock Titan
Context Therapeutics Begins Phase 1 Trial of CT-95 Targeting Mesothelin-Expressing Cancers - MSN
Earnings Report: Is Klaviyo Inc attractive for institutional investorsLong Setup & Daily Chart Pattern Signals - baoquankhu1.vn
Context Therapeutics (NASDAQ:CNTX) Upgraded to Hold at Wall Street Zen - MarketBeat
How cyclical is Context Therapeutics Inc.’s revenue streamProfit Target & Real-Time Buy Signal Notifications - mfd.ru
Bank Watch: Does ABRPRD have pricing powerPortfolio Profit Report & Verified Technical Trade Signals - baoquankhu1.vn
Is WisdomTree Europe Hedged Equity Fund stock among top earnings playsJuly 2025 Price Swings & Comprehensive Market Scan Reports - mfd.ru
Will AGF A S (5IN) stock return to pre crash levelsQuarterly Growth Report & Smart Swing Trading Alerts - mfd.ru
ALNA Allena Pharmaceuticals NASDAQ Intraday 12 Feb 2026: Volume up at $0.075 - Meyka
Context Therapeutics to Participate in Upcoming Investor Conferences - The Globe and Mail
SYNI stock: Synvista Therapeutics (PNK) $0.000001 on 10 Feb 2026, oversold bounce - Meyka
Biotech firm Context Therapeutics lines up four investor conferences - Stock Titan
Context Therapeutics (NASDAQ:CNTX) Lowered to Sell Rating by Wall Street Zen - Defense World
Compass Therapeutics (NASDAQ:CMPX) Cut to “Sell” at Wall Street Zen - Defense World
Market Wrap: Is PARR forming a breakout pattern2025 Market Sentiment & Stepwise Trade Signal Guides - baoquankhu1.vn
E.On (FRA:EOAN) Shares Cross Above 200 Day Moving Average – What’s Next? - Defense World
Oppenheimer initiates Whitehawk Therapeutics (WHWK) with Outperform Feb 2026 - Meyka
ALNA Allena Pharma NASDAQ Pre-Mkt 06 Feb 2026: Vol 252.31M watch catalyst - Meyka
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Aug Spikes: What is Context Therapeutics Incs book value per share2025 Sector Review & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Situation - Yahoo Finance
THCT stock rises 4,650% to $0.019 on PNK: short-term volume spike flags high volatility - Meyka
Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement - Finviz
Finanzdaten der Context Therapeutics Inc-Aktie (CNTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Context Therapeutics Inc-Aktie (CNTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Levit Alex C. | Chief Legal Officer, Corp. Sec |
Jun 06 '25 |
Buy |
0.58 |
20,000 |
11,520 |
29,000 |
| Minai-Azary Jennifer Lynn | Chief Financial Officer |
Jun 06 '25 |
Buy |
0.64 |
40,010 |
25,486 |
80,010 |
4.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):